Recently, hydroxychloroquine sulfate tablets produced by Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd., a subsidiary of Shanghai Pharmaceutical, received a drug registration certificate issued by the Philippine Food and Drug Administration, and the drug was approved for marketing. Hydroxychloroquine sulfate tablets are mainly used for rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, and skin diseases caused or exacerbated by sunlight.

Recently, hydroxychloroquine sulfate tablets produced by Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd., a subsidiary of Shanghai Pharmaceutical, received a drug registration certificate issued by the Philippine Food and Drug Administration, and the drug was approved for marketing. Hydroxychloroquine sulfate tablets are mainly used for rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, and skin diseases caused or exacerbated by sunlight.